[1] Amin A A, Alabsawy E I,Jalan R, et al. Epidemiology,pathophysiology, and management of hepatorenal syndrome[J]. Seminar Nephrol, 2019, 39(1): 17-30.
[2] Velez J, Therapondos G, Juncos L A. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol, 2020,16(3):137-155.
[3] Wang L, Long Y, Li K X, et al. Pharmacological treatment of hepatorenal syndrome: a networkmeta-analysis[J]. Gastroenterol Rep(Oxf), 2020,8(2):111-118.
[4] Arroyo V, Ginès P, Gerber A L, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis-International Ascites Club[J]. Hepatology, 1996,23(1):164-176.
[5] Angeli P, Garcia-Tsao G, Nadim M K, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites(ICA) consensus document[J].J Hepatol, 2019, 71(4): 811-822.
[6] Biggins S W, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluatiou, and management of ascites, spontaneous bacterial peritonitis and hepa-to renal syndrome: 2021 practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021,74(2):1014-1048.
[7] Kazory A, Ronco C. Hepatorenal syndrome or hepatoa diorenal syndrome: revisiting basic concepts in view of emerging data[J]. Car diorenal Med, 2019, 9(1):1-7.
[8] Alukal J J, John S, Thuluvath P J. Hyponatremia in cirrhosis: an update[J]. Am J Gastroenterol, 2020, 115(11): 1775-1785.
[9] Ginès P, Guevara M. Hyponatremia in eirrhosis:pathogenesis:pathogenesis, clinical signiflcance, and management[J]. Hepatology, 2008, 48(3): 1002-1010.
[10] Klm H Y, Cho E J, Chun S, et al. Red blood cell alloimmunization in Korean patients with Myelodysplastic syndrome and liver cirrhosis[J]. Ann Lab Med, 2019, 39(2): 218-222.
[11] Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J].Hepatology, 2020,71(2):600-610.
[12] Schuler R W,Arroyo V,Bernard M,et al.Peripheral arterial vasodilation hypothesis:aproposal for the initiation of renal sodium and water retention in cirrhosis[J].Hepatology,1988,8(5):1151-1157.
[13] Liu H, Jayakumar S, Traboulsi M, et al. Cirrhotic cardiomyopathy: implications for liver transplantation[J]. Liver Transpl,2017,23(6):826-835.
[14] Fuhrmann V, Krowka M. Hepatopulmonary syndrome[J]. J Hepatol, 2018, 69(3): 744-745.
[15] 刘建军,郑文凯,王江红,等.终末期肝病血管活性物质抵抗发生机制与诊疗关系的争议和对策[J].临床肝胆病杂志,2022,38(10):2408-2411.
[16] 郑文凯,刘建军,刘研,等.终末期肝病周围循环功能障碍发生原因和机制与临床关系[J].肝脏杂志,2022,27(5):606-609.
[17] 中华医学会肝病学分会.肝硬化腹水诊疗指南(2023年版)[J].中华肝脏病杂志,2023,31(8):813-826.
[18] Moore K,Jaml K,Verleger K, et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome[J].Aliment Pharmacol Ther, 2020, 52(2):351-358.
[19] Nguyen-tat M,Jagger J,Rey J W, et al.Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2[J].United European Gastroenterol J, 2019,7(4):529-537.
[20] 刘建军,郑文凯,王江红,等.对2021年美国肝病学会腹水和肝肾综合征的诊断、评估和管理指南的质疑与临床实践[J].胃肠病学和肝病学杂志,2022,31(2):121-125.
[21] Jia J D, Xie W, Ding H G, et al.Utility and safety of tolvaotan in cirrhotic patients with hyponatremia:a prospective coherent study[J].Ann Hepatol,2017,16(1):123-132.
[22] Wong F, Moore K, Dlngemanse J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome[J].Hepatology, 2008,47(1):160-168.
[23] 刘建军,郑文凯,高廷廷,等. 制订中国知识产权肝硬化腹水和肝肾综合征诊疗指南的必要性和可行性[J]. 中国临床研究杂志,2023,36(12):1875-1880.
[24] Wang P L,Silver S A,Djerboua M,et al.Recovery from dialysis-treated acute kidney injury in patients with cirrhosis:a population-based study[J].Am J Kidney Dis,2022,80(1):55-64.
[25] Allegretti A S,Parada X V,Eneanya N D,el al.Prognosis of patients with cirrhosis and AKI who initiate RRT[J].Cli J Am Soc Nephrol,2018,13(1):16-25.
[26] Lepida A,Marot A,Trépo E, et al.Systematic review with meta-analysis:automated low-flow ascites pump therapy for refractory ascites[J].Aliment Pharmacol Ther,2019,50(9):978-897.
[27] Cavallin M,Kamath P S,Merli M, et al.Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:a randomized trial[J].Hepatology,2015,62(2)567-574.
[28] Adebayo D,Leong S F,Wong F. Refractory ascites in Liver cirrhosis[J].Am J Gastroenterol,2019,114(1):40-47.
[29] Boyer T D,Sanyal A J,Wong F, et al.Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1[J].Gastroenterology,2016,150(7):1579-1589.
[30] Kinugawa K,Sato N,Inomata T, et al.Novel risk score efficiently prevents Tolvaptan induced hypernatremia events in patients with heart failure[J].Cir,2018,82(5):1344-1350.
[31] 朱庆华,高成斌,刘建青,等.肝硬化腹水低钠血症与精氨酸加压素关系和V2受体拮抗剂应用的争议问题[J].胃肠病学和肝病学杂志,2023,32(12):1419-1422.
[32] Tang J,Wang Y,Han T, et al.Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses:a phase Ⅲ clinical trial[J].BMC Gastroenterol,2022,20(1):391.
[33] Bellows I,Kontxoglou K,Psyrri A, et al.Toivaptan response improves overall survival inpatients with refractory ascites:a meta-analysis[J].Dig Dis,2020,38,(4):320-328.
[34] Wong F,Watson H,Gerber A, et al.Satavaptan for the management of ascites in cirrhosis:efficacy and safety across the spectrum of ascites severity[J]. Gut, 2012, 61(1):108-116.
[35] Shah N,Mcdaniel R,Alkan M, et al.A perspective on diuretic resistance in chronic congestiv heart failure[J].Ther Adv Cardiovasc Dis, 2017,11(10):271-278. |
